Details of the Drug Combination

General Information of Drug Combination (ID: DCMT95V)

Drug Combination Name
SY-1425 Valrubicin
Indication
Disease Entry Status REF
Melanoma Investigative [1]
Component Drugs SY-1425   DMH8UF0 Valrubicin   DMOYJFK
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: MALME-3M
Zero Interaction Potency (ZIP) Score: 1.31
Bliss Independence Score: 1.71
Loewe Additivity Score: 3.05
LHighest Single Agent (HSA) Score: 4.18

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of SY-1425
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [2]
Myelodysplastic syndrome 2A37 Phase 1 [2]
SY-1425 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Retinoic acid receptor alpha (RARA) TTW38KT RARA_HUMAN Agonist [2]
------------------------------------------------------------------------------------
Indication(s) of Valrubicin
Disease Entry ICD 11 Status REF
Bladder cancer 2C94 Approved [3]
In situ carcinoma N.A. Approved [4]
Urinary bladder cancer N.A. Approved [4]
Psoriasis vulgaris EA90 Phase 2 [5]
Valrubicin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Valrubicin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [7]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DC0CDNZ HL-60(TB) Investigative [8]
Plasma cell myeloma DCBQJVD RPMI-8226 Investigative [8]
Renal cell carcinoma DC2JDXA UO-31 Investigative [8]
Carcinoma DCFKA4U MCF7 Investigative [9]
Invasive ductal carcinoma DCCJL8D HS 578T Investigative [9]
Adenocarcinoma DCO10C3 HCC-2998 Investigative [1]
Adenocarcinoma DC7Y7N0 HCT-15 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
4 Valrubicin FDA Label
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 Metabolic activation of N-acylanthracyclines precedes their interaction with DNA topoisomerase II. NCI Monogr. 1987;(4):111-5.
7 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
8 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
9 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.